Hinge Bio Secures $30M for GEM-DIMER Therapeutics Development
Hinge Bio, a privately-held biotechnology company based in Burlingame, California, has successfully secured $30 million in Series A financing. This funding round was led by Point72, with significant contributions from Ridgeback Capital, InVivium Capital, and Lightswitch Capital, among other investors.
The primary objective of this financing is to support the entry of Hinge Bio’s lead product candidate, HB2198, into a Phase 1 clinical trial. HB2198 is designed to treat patients living with Systemic Lupus Erythematosus (Lupus), a chronic autoimmune disease that affects various parts of the body. Additionally, the funds will be used to develop additional therapeutics from Hinge Bio’s proprietary GEM-DIMER platform to address diseases with high unmet need.
Hinge Bio’s GEM-DIMER technology is a groundbreaking platform that enables the creation of multivalent, multispecific antibody-based therapeutics. These therapeutics are designed to bind their targets cooperatively, allowing for dramatically enhanced biological activity and unique functionality. The GEM-DIMER platform has broad applicability across therapeutic areas and constructs, making it a promising tool for developing innovative medicines.
HB2198, the lead candidate from the GEM-DIMER platform, is expected to enter clinical development during 2025. The program aims to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20 with enhanced natural killer cell engagement. Pre-clinical studies have demonstrated deeper and more rapid B cell depletion than has been reported for other antibody-based therapies. The therapeutic goal of HB2198 is to achieve a reset of the immune system through rapid and deep B cell depletion in both peripheral blood and lymphoid tissues, offering convenience, accessibility, cost, and safety benefits of an off-the-shelf antibody-based therapeutic.
Hinge Bio is committed to developing life-changing medicines for patients with intractable diseases. The company’s pipeline focuses on autoimmune diseases, with plans to expand into other therapeutic areas. The GEM-DIMER technology was invented by Hinge Bio’s Chief Scientific Officer, Daniel Capon, Ph.D., who has a proven track record of developing foundational technologies that have transformed biological therapy.
The investment in Hinge Bio reflects the confidence of the investors in the company’s innovative approach and the potential of the GEM-DIMER platform to revolutionize the treatment of autoimmune diseases. With this funding, Hinge Bio is well-positioned to advance its pipeline and bring new hope to patients suffering from these debilitating conditions.
Hinge Bio’s leadership team, led by Chief Executive Officer Barry Selick, Ph.D., has extensive experience in biotechnology and pharmaceutical development. Dr. Selick has a strong background in leading biotechnology companies and has been instrumental in driving innovation and growth in the industry.
The successful completion of this Series A financing marks a significant milestone for Hinge Bio, enabling the company to accelerate its research and development efforts. With its proprietary GEM-DIMER platform and a strong leadership team, Hinge Bio is poised to make a significant impact in the biotechnology industry and improve the lives of patients worldwide.
See more funded startups in USA.